For a patient with limited/resectable metastatic melanoma and no evidence of disease after resection, when would you consider doublet immunotherapy rather than nivolumab or pembrolizumab monotherapy?  

For instance, in a patient with isolated distant nodal involvement who had the lymph node resected but did not have a lymph node dissection?



Answer from: Medical Oncologist at Academic Institution